Cardiometabolic diseases are increasingly recognized as interconnected dysfunction affecting the heart, vasculature, kidneys, liver, and metabolic system. The rise in obesity, insulin resistance, and diabetes has highlighted the need for a more comprehensive approach to understanding these conditions. A multidimensional staging system, the cardioVascular-kidney-liver-metabolic (CVKLM) framework, is presented. This framework independently grades involvement across these five organ systems, ranging from absent to advanced.
CVKLM Framework Overview
This framework utilizes a standardized language similar to tumor staging, describing disease severity within each organ and its distribution. CVKLM integrates established classifications including heart failure stages, vascular risk assessment, KDIGO chronic kidney disease stratification, metabolic dysfunction-associated steatotic liver disease (MASLD) criteria, contemporary definitions of diabetes, and clinical obesity. Unlike single-stage systems, CVKLM preserves organ-specific information and records coexisting abnormalities across domains.
Framework Purpose and Future Directions
The framework is intended for clinical and research phenotyping and staging. It is designed to facilitate the systematic recognition of concomitant organ disease and to support existing diagnostic, referral, and treatment pathways. The prognostic significance and clinical utility of CVKLM profiles are yet to be determined. This framework offers a pragmatic approach to encompassing the full spectrum of cardiometabolic disease, from preclinical involvement to advanced multiorgan failure. MASLD is a key component of this assessment.